Impact and potential value of immunosenescence on solid gastrointestinal tumors

Front Immunol. 2024 Jun 28:15:1375730. doi: 10.3389/fimmu.2024.1375730. eCollection 2024.

Abstract

Solid gastrointestinal tumors often respond poorly to immunotherapy for the complex tumor microenvironment (TME), which is exacerbated by immune system alterations. Immunosenescence is the process of increased diversification of immune genes due to aging and other factors, leading to a decrease in the recognition function of the immune system. This process involves immune organs, immune cells, and the senescence-associated secretory phenotype (SASP). The most fundamental change is DNA damage, resulting in TME remodeling. The main manifestations are worsening inflammation, increased immunosuppressive SASP production, decreased immune cell antitumor activity, and the accumulation of tumor-associated fibroblasts and myeloid-derived suppressor cells, making antitumor therapy less effective. Senotherapy strategies to remove senescent cells and block key senescence processes can have synergistic effects with other treatments. This review focuses on immunoenescence and its impact on the solid TME. We characterize the immunosenescent TME and discuss future directions for antitumor therapies targeting senescence.

Keywords: colorectal cancer; gastrointestinal tumors; immunosenescence; immunotherapy; tumor microenvironment.

Publication types

  • Review

MeSH terms

  • Animals
  • Cellular Senescence / immunology
  • Gastrointestinal Neoplasms* / immunology
  • Gastrointestinal Neoplasms* / therapy
  • Humans
  • Immunosenescence* / immunology
  • Immunotherapy / methods
  • Senescence-Associated Secretory Phenotype / immunology
  • Tumor Microenvironment* / immunology

Grants and funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. National Natural Science Foundation of China (82072750, 82203137), Shanghai Sailing Program (21YF1459300), Shanghai Municipal Health Commission Health Industry Clinical Research Project (20224Y0348).